Jazirehi, Ali R <br/><br/>
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.  [electronic resource] 

 -  Oncogene  Mar 2005 
 - 2121-43 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>0950-9232 
<br/><br/><label>Standard No.: </label>10.1038/sj.onc.1208349  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD--drug effects<br/>Antigens, CD20--drug effects<br/>Antineoplastic Agents--therapeutic use<br/>Cell Survival--drug effects<br/>Cloning, Molecular<br/>Humans<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Mice<br/>Recombinant Fusion Proteins--therapeutic use<br/>Rituximab<br/>Signal Transduction--drug effects